Ryszard Wichary

  • Citations Per Year
Learn More
INTRODUCTION Imatinib mesylate (IM) remains the treatment of choice for chronic myeloid leukemia (CML) showing a remarkable efficacy and offers a perspective for long disease-free survival. Due to prolonged administration of IM, the questions about the possible impact on the development of secondary malignancies (SM) are raised. OBJECTIVE To investigate(More)
Lenalidomide has been approved for the treatment of lower-risk myelodysplastic syndrome (MDS) with 5q deletion (del(5q)). We present for the first time a retrospective analysis of low-risk MDS with isolated del5q treated with lenalidomide, outside the clinical trials. 36 red blood cell (RBC) transfusion-dependent patients have been included in the study.(More)
Interdigitating dendritic cell sarcoma (IDCS) is an extremely rare neoplastic proliferation of dendritic cells [1]. EBV and HSV8 viral infections are thought to be involved in its pathogenesis, but understanding their role requires further studies [2]. IDCS usually affects adults with a median age at diagnosis of 51 years. Clinical manifestation usually(More)
Data on safety and efficacy of ruxolitinib treatment in myeloproliferative neoplasms (MPN) with concomitant thrombocytopenia are scarce and limited to patients with myelofibrosis (MF). It was demonstrated that 11–16% of MF patients had platelet (PLT) count \50 9 10/l at diagnosis and the rate of thrombocytopenia increases with disease progression.(More)
  • 1